Piramal Pharma Ltd. Share Price Target from 2025 to 2050: Future Outlook
Piramal Pharma Ltd. is a leading Indian pharmaceutical company with a global footprint in drug development, life sciences, and manufacturing of APIs and complex formulations. Known for its high-quality contract development and manufacturing services (CDMO), Piramal Pharma combines innovation, scale, and regulatory compliance. In this post, we explore Piramal Pharma’s share price outlook from 2025 through 2050, analyzing its core operations, growth potential, and long-term investment case.
Piramal Pharma Ltd. Overview: Growth, Products, & Market Presence
Piramal Pharma operates in three verticals: CDMO services for global clients, active pharmaceutical ingredient (API) manufacturing, and patented and generic drug formulations. It serves global life sciences companies, biotech startups, and pharmaceutical firms across North America, Europe, and India, leveraging scale and execution excellence to win regulated-market contracts.
| Details | Information |
|---|---|
| Founded | 1988 (as Piramal Healthcare; Pharma demerged in 2020) |
| Headquarters | Mumbai, Maharashtra, India |
| Sector | Pharmaceuticals & Life-Sciences Services |
| Key Segments | CDMO, APIs, Formulations |
| Stock Listings | NSE: PPHPL / BSE: 543253 |
| Market Presence | Global contracts in USA, Europe; manufacturing plants across India |
On this page, you will find detailed insights into Piramal Pharma Ltd.’s stock, including real-time prices, technical analysis, and long-term forecasts:
✅ Real-Time Stock Price: Automatically updated every minute for the latest market data.
✅ Technical Indicators: Adjusted based on specific time frames to provide timely trading insights.
✅ Financial Reports: Updated quarterly to reflect the company’s latest financial performance.
✅ Stock Charts: Refreshed every minute for real-time visual analysis.
📊 Note: Piramal Pharma Ltd.’s stock forecast prices in the tables are automatically updated based on live asset price changes.
Piramal Pharma Ltd. Financial Overview & Key Metrics
Piramal Pharma emphasizes repeat CDMO contracts, regulatory compliance, and capacity scale-up. The company manages costs through backward integration, operational efficiency, and capital discipline—preparing for future profitability uplift.
Below is a detailed breakdown of its key financial figures—including revenue, net profit, earnings per share (EPS), and other crucial metrics. These insights enable investors to assess the company’s financial health and long-term growth potential.
Use the landscape mode for best viewing on mobile devices.
Investment Potential & Associated Risks
Why Consider Investing in Piramal Pharma Ltd.?
- Leading Global CDMO Profile
Contract wins and multi-year partnerships with regulated-market players give Piramal Pharma strong visibility and recurring revenue streams. - Integrated API and Formulations Offerings
Owning APIs through to finished dosage forms allows the company to capture higher value in the value chain and protect margins. - Scale and Regulatory Expertise
GMP-compliant manufacturing, multiple certifications, and a robust quality infrastructure enable access to high-barrier markets. - Capacity Expansion in High-Demand Spaces
Ongoing investments in complex APIs and biosimilars capacity respond to rising global demand for outsourced R&D and manufacturing. - Leveraging High-Margin Specialty Products
Focus on controlled substances, niacinamide, oncology APIs, and high-potency injectables supports a move toward specialty revenue streams.
Risks to Consider
- Regulatory and Compliance Risk
Pharma manufacturing in regulated markets requires constant oversight; any compliance issue could disrupt contracts or revenues. - CDMO Client Concentration
Dependency on a few large global partners can leave the business vulnerable if contracts aren’t renewed or scaled up. - Generic Competition
For off-patent formulations, price erosion and competition from low-cost manufacturers may impact margins. - Execution Risk in Expansion
Timely commissioning of new facilities and ramp-up of biosimilar/API lines is essential to avoid delays in revenue growth. - Macro‑Healthcare Policy Changes
Changes in drug pricing regulation, patent laws, or trade norms could affect export earnings and strategic planning.
Piramal Pharma Share Price Target: Tomorrow & Weekly Outlook
Piramal Pharma stock price forecasts for tomorrow and the upcoming week are based on recent market trends, historical price movements, and key technical indicators. These projections offer valuable insights into potential price changes, helping traders and investors make informed decisions.
However, various factors can influence stock prices—including market sentiment, news updates, and global events—so it’s always wise to stay updated and flexible with strategies.
📊 Below, you’ll find the expected stock price targets for the coming days:
| Date | Min. Price | Max. Price | Stock Price |
|---|---|---|---|
| 23-Jun | 188.55 | 198.24 | 193.44 |
| 24-Jun | 185.86 | 195.75 | 190.95 |
| 25-Jun | 185.02 | 194.59 | 189.93 |
| 26-Jun | 184.68 | 194.71 | 189.65 |
| 27-Jun | 183.59 | 193.25 | 188.59 |
| 30-Jun | 185.40 | 195.41 | 190.53 |
| 01-Jul | 183.10 | 193.33 | 188.04 |
| 02-Jul | 182.43 | 191.86 | 187.02 |
| 03-Jul | 181.89 | 191.70 | 186.75 |
| 04-Jul | 180.68 | 190.43 | 185.68 |
Technical Analysis of Piramal Pharma Ltd. Using Key Indicators
For Piramal Pharma Ltd., you can leverage indicator-based technical analysis to identify optimal market entry and exit points. Adjust the time frame according to your trading strategy for more accurate insights.
How to Interpret Technical Analysis Signals:
✅ “Sell” or “Strong Sell” – Indicates bearish (negative) market sentiment, suggesting a potential decline.
✅ “Buy” or “Strong Buy” – Indicates bullish (positive) market sentiment, signaling a potential uptrend.
Time Frame Considerations:
- Medium to Long-Term Analysis: If you plan to hold for more than a week, use daily to weekly time frames.
- Short-Term Analysis (Intraday/Short Swing Trading): Use time frames ranging from 15 minutes to 2 hours.
Below, you’ll find technical indicator-based buy and sell signals based on different time frames to assist in your investment decisions.
Future Growth Drivers for Piramal Pharma Ltd.
- CDMO Order Book Growth
As global companies seek cost-efficient and compliant outsourcing, Piramal can scale up contract volumes and diversify its client base. - Backward Integration Success
Leveraging internal API capabilities to feed its CDMO and formulation units ensures margin control and supply security. - Specialty API & Biosimilars Uptick
Building capability in complex, high-margin molecules and biosimilar APIs aligns with future healthcare trends and pricing power. - New Plant & Capability Additions
Commissioning new production lines in high-potency and controlled ingredients enhances product mix and scale economics. - Geographic Market Expansion
Entering new regulated-card grey or regulated-market regions via partner networks boosts global footprint and revenue diversification.
What Will Drive Piramal Pharma’ Share Price Over the Coming Decades?
- Multi-year CDMO contract growth and renewals in regulated markets.
- Specialty API ramp-up with a focus on high-value therapeutic areas.
- Cost efficiency and margin expansion through backward integration.
- Capacity execution and biosimilars capability build influencing future recognition.
- Diversified global exposure reducing risk of region-specific headwinds.
Piramal Pharma Share Price Target & Forecast (2025-2050)
This long-term stock price forecast for Piramal Pharma Ltd. is based on historical market trends, the company’s growth prospects, and industry analysis. While forecasting stock prices for the long term involves uncertainty, these forecasts help investors gain an understanding of potential future price moves.
📊 The following table presents the Piramal Pharma share price target forecast from 2025 to 2050, based on current market trends and available data.
| Year | Min. Price | Max. Price |
|---|---|---|
| 2025 | Forecasted stock is currently unavailable. Please check back later. | |
| 2026 | ||
| 2027 | ||
| 2028 | ||
| 2029 | ||
| 2030 | ||
| 2031 | ||
| 2032 | ||
| 2033 | ||
| 2034 | ||
| 2035 | ||
| 2040 | ||
| 2050 |
The Piramal Pharma Ltd. share price targets provided here are for informational purposes only. Both short-term and long-term stock price predictions are based on historical data and market trends, but actual prices may vary due to market fluctuations and external factors. This forecast assumes positive market conditions and does not account for unforeseen risks, economic uncertainties, or company-specific challenges. Investors should conduct their research before making any financial decisions.
Live Stock Chart & Price Trends – Piramal Pharma Ltd.
Keep track of Piramal Pharma Ltd.’s stock performance with our live chart below. This real-time tool displays the latest price movements, trading volume, and market trends to help investors and market watchers stay informed. You can easily switch between intraday, daily, weekly, or monthly views and apply various technical indicators to deepen your analysis. Whether you’re actively trading or just keeping an eye on the market, this chart offers everything you need to make smart, timely decisions.
IVP Ltd. Share Price Target: Future Outlook
IVP Ltd. is a leading manufacturer of foundry chemicals and resins, serving the automotive, engineering, and construction industries. READ MORE
Expert Opinions & Market Sentiment
Brokerage & Analyst Ratings
Analysts generally rate Piramal Pharma as “Accumulate” or “Buy,” citing its robust CDMO pipeline and specialty API expansion—while watching execution of new capacity and client diversification.
Investor Sentiment & Market Trends
- Institutional Investors: Largely positive, attracted by strong contract visibility and regulated-market focus.
- Retail Participation: Picking up interest as specialty pipeline and earnings profile become visible.
- Market Mood: Optimistic, contingent on capacity ramp-up, CDMO performance, and absence of regulatory disruptions.
Frequently Asked Questions (FAQ)
Is Piramal Pharma Ltd. a good long‑term investment?
Yes. Its CDMO-led business, integrated API-formulation model, and entry into specialty therapeutics make it well-positioned for long-term growth.
What are the main growth drivers?
Drivers include CDMO revenue scaling, specialty API expansion, backward integration, global market access, and capacity ramp-up.
Does Piramal Pharma pay dividends?
Yes, the company pays dividends based on profits—though the payout may reflect reinvestment into growth programs.
How does it compare with other pharmaceutical giants?
It competes strongly in CDMO and specialty APIs vs peers, backed by integrated capabilities and compliance credentials that many companies lack.
Price Prediction Methodology
Our stock price forecasts are based on a combination of analytical techniques to provide a well-rounded outlook:
✅ Expert Consensus & Market Sentiment – Predictions incorporate expert opinions and market sentiment analysis to enhance accuracy.
✅ Technical Analysis – Price movements are analyzed using historical charts and indicators, focusing on medium- and long-term trends for better precision.
✅ Statistical Models – Various statistical techniques assess the probability, type, and impact of fundamental factors influencing price changes.
✅ Predictive Algorithms – Advanced machine learning and statistical models leverage historical data patterns to estimate future price movements.
📊 Note: While these methods enhance prediction accuracy, stock prices are subject to market volatility and unforeseen economic factors.
